Anti-NMDA Receptor Encephalitis clinical trials at UCSF
1 research study open to eligible people
Anti-NMDA receptor encephalitis is a brain disease that causes immune attacks on brain cells and sudden changes in thinking or behavior. UCSF is studying an antibody treatment given by infusion to measure safety and drug levels. UCSF is also tracking symptoms and collecting samples for lab study.
Showing trials for
(PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
open to eligible people ages 12 years and up
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
San Francisco, California and other locations
Our lead scientists for Anti-NMDA Receptor Encephalitis research studies include Jeffrey Gelfand.
Last updated: